Danielle Binler
Pain Medicine · South Weymouth, MANPI 1952764383
Payments from drug & device makers
What this record shows
9 manufacturers reported payments, led by Abbott at 52.0% of the total. Reporting peaked in 2022 at $3,638 and has fallen 91.8% since, to $299 in 2024.
Across 50 payments — averaging $105.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Nevro Corp.$874
- Boston Scientific$742
- Medtronic$650
- Saluda Medical Americas, Inc.$99
- Stimwave Technologies Incorporated$62
- plus $99 from 3 others
What the payments were for
- Travel & lodging$2,26043%
- Food & beverage$3,00257%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $2,736 |
| Nevro Corp. | 8 | $874 |
| Boston Scientific | 13 | $742 |
| Medtronic | 7 | $650 |
| Saluda Medical Americas, Inc. | 1 | $99 |
| Stimwave Technologies Incorporated | 1 | $62 |
| SPR Therapeutics, Inc | 1 | $53 |
| Vertos Medical, Inc. | 1 | $25 |
| AbbVie | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$2,241
- Omnia$532
- INTELLIS ADAPTIVESTIM$474
- Senza$238
- GENERAL PAIN MANAGEMENT$191
- Superion Indirect Decompression System$154
- SUPERION$123
- INTELLIS$118
How this compares
$5,262 in reported general payments places this provider in the 75th percentile of 137 pain medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 59 | $480 |
| Meloxicam | 11 | $209 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in South Weymouth
- Hariharan SundramNewton$1.7M
- Thomas SimopoulosBoston$181K
- Ivan UritsWareham$70K
- Antje BarreveldNewton$64K
- Arti OriBoston$62K
- Christine SangBoston$56K
- Ali EbrahimiBurlington$41K
- Alexandra AdlerLowell$35K
- Eduard VaynbergBoston$32K
- David GarasNatick$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.